Main Menu

FibroGen, Inc.

(NASDAQ GS: FGEN)

Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of FibroGen, Inc. ("FibroGen") on behalf of stockholders.  A class action complaint has been filed against FibroGen, which alleges that FibroGen's press releases, investor presentations, and public filings contained materially false and misleading statements and/or omitted material facts concerning FibroGen's financial condition, which included, among other misrepresentations, statements concerning Roxadustat's purported safety and efficacy, its Phase 3 trial results, the drug's NDA approval process, and its prospects for FDA approval.

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to info@rl-legal.com.

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 05/16/2022


* Indicates a required field.

Back to Page